SEARCH:   Advanced

Blood, 1 November 2005, Vol. 106, No. 9, pp. 2977-2981. Prepublished online as a Blood First Edition Paper on July 14, 2005; DOI 10.1182/blood-2005-02-0691. This Article Full Text (PDF) All Versions of this Article: 2005-02-0691v1 106/9/2977    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Richardson, P. G Articles by Anderson, K. C Search for Related Content PubMed PubMed Citation Articles by Richardson, P. G Articles by Anderson, K. C Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 18, 2005 Accepted June 10, 2005 Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma Paul G Richardson*, Bart Barlogie, James Berenson, Seema Singhal, Sundar Jagannath, David Irwin, S. V Rajkumar, Teru Hideshima, Hugh Xiao, Dixie Esseltine, David Schenkein, and Kenneth C Anderson Dana-Farber Cancer Institute, Boston, MA, USA University of Arkansas for Medical Sciences, Littlerock, AR, USA Cedars-Sinai Medical Center, Los Angeles, CA, USA Northwestern Memorial Hospital, Chicago, IL, USA St Vincent's Comprehensive Cancer Center, New York, NY, USA Alta Bates Cancer Center, Berkeley, CA, USA Mayo Clinic, Rochester, MN, USA Millennium Pharmaceuticals, Inc., Cambridge, MA, USA * Corresponding author; email: Paul_Richardson{at}DFCI.Harvard.edu. Bortezomib, a potent and reversible proteasome inhibitor, affects the myeloma cell and its microenvironment, resulting in downregulation of growth and survival signaling pathways and durable responses in patients with relapsed and refractory myeloma. Potential associations between baseline parameters and outcomes with bortezomib were explored in 202 patients who received bortezomib 1.3 mg/m2 twice weekly for 2 weeks every 3 weeks for up to 8 cycles in a phase 2 trial. Using European Group for Blood and Marrow Transplantation criteria, the response rate (complete or partial response) to bortezomib alone was 27% and not associated with sex, race, performance status, isotype, chromosome 13 deletion, number or type of previous therapies, or concentration of hemoglobin or 2-microglobulin. By multivariate analysis, factors associated with lower response were age 65 versus < 65 years (19% vs 32%; P < .05) and > 50% versus 50% plasma cell infiltration in bone marrow (20% vs 35%; P < .05). Factors that may be indicative of tumor burden (bone marrow plasma cell infiltration > 50%, hypoalbuminemia, thrombocytopenia) were predictive of overall survival. Chromosome 13 deletion and elevated 2-microglobulin, generally considered poor prognostic factors, were not predictive of poor outcome with bortezomib in this study. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. K Kettle, K. L Finkbiner, S. E Klenke, R. D Baker, D. W Henry, and C. B Williams Initial therapy in multiple myeloma: investigating the new treatment paradigm Journal of Oncology Pharmacy Practice, September 1, 2009; 15(3): 131 - 141. [Abstract] [PDF] G. Bianchi, L. Oliva, P. Cascio, N. Pengo, F. Fontana, F. Cerruti, A. Orsi, E. Pasqualetto, A. Mezghrani, V. Calbi, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition Blood, March 26, 2009; 113(13): 3040 - 3049. [Abstract] [Full Text] [PDF] P. Baumann, S. Mandl-Weber, A. Volkl, C. Adam, I. Bumeder, F. Oduncu, and R. Schmidmaier Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells Mol. Cancer Ther., February 1, 2009; 8(2): 366 - 375. [Abstract] [Full Text] [PDF] M. A. Dawson, S. S. Opat, Y. Taouk, M. Donovan, M. Zammit, K. Monaghan, N. Horvath, A. W. Roberts, H. M. Prince, M. Hertzberg, et al. Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma Clin. Cancer Res., January 15, 2009; 15(2): 714 - 722. [Abstract] [Full Text] [PDF] A. Palumbo, F. Gay, S. Bringhen, A. Falcone, N. Pescosta, V. Callea, T. Caravita, F. Morabito, V. Magarotto, M. Ruggeri, et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma Ann. Onc., June 1, 2008; 19(6): 1160 - 1165. [Abstract] [Full Text] [PDF] P. G. Richardson, C. Mitsiades, R. Schlossman, N. Munshi, and K. Anderson New Drugs for Myeloma Oncologist, June 1, 2007; 12(6): 664 - 689. [Abstract] [Full Text] [PDF] A. Palumbo, M. T. Ambrosini, G. Benevolo, P. Pregno, N. Pescosta, V. Callea, C. Cangialosi, T. Caravita, F. Morabito, P. Musto, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma Blood, April 1, 2007; 109(7): 2767 - 2772. [Abstract] [Full Text] [PDF] W.-Z. Ying, H.-G. Zhang, and P. W. Sanders EGF Receptor Activity Modulates Apoptosis Induced by Inhibition of the Proteasome of Vascular Smooth Muscle Cells J. Am. Soc. Nephrol., January 1, 2007; 18(1): 131 - 142. [Abstract] [Full Text] [PDF] P. G. Richardson, T. Hideshima, and K. C. Anderson Plasma cell dyscrasias ASH Self-Assessment Program, January 1, 2007; 2007(1): 298 - 327. [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020